Rohtak News Magazine

Interleukin (IL) Inhibitors Market Worth USD 74.6 Billion By 2026 Growing At A CAGR Of 17.4% | Grand View Research, Inc.

 Breaking News
  • No posts were found

Interleukin (IL) Inhibitors Market Worth USD 74.6 Billion By 2026 Growing At A CAGR Of 17.4% | Grand View Research, Inc.

July 21
09:24 2021
Interleukin (IL) Inhibitors Market Worth USD 74.6 Billion By 2026 Growing At A CAGR Of 17.4% | Grand View Research, Inc.

“Grand View Research, Inc. – Market Research And Consulting.”
According to a new report published by Grand View Research, Growing prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors are expected to drive the IL Inhibitors market growth.

The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD). 

Interleukin Inhibitors Market Report Highlights

 Psoriatic arthritis and IBD are projected to register fastest growth through to 2026

IL-17 is likely to overtake IL-23 as the leading type by 2026

IL-5 inhibitors for asthma to witness strong growth in the near future

Asia Pacific is expected to exhibit the fastest regional growth.

Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

For Requesting a Sample Copy Please Visit @ https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market/request/rs15

Interleukin Inhibitors Market Segmentation

Grand View Research has segmented the global interleukin inhibitors market based on application, type, and region:

Interleukin Inhibitors Application Outlook (Revenue, USD Million, 2014 – 2026)
    • Psoriasis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Asthma
    • Inflammatory Bowel Disease
    • Others

Interleukin Inhibitors Type Outlook (Revenue, USD Million, 2014 – 2026)
    • IL-1
    • IL-5
    • IL-6
    • IL-17
    • IL-23
    • Others

Interleukin InhibitorsRegional Outlook (Revenue, USD Million, 2014 – 2026)
     North America
        • The U.S.
        • Canada
    • Europe
        • Germany
        • The U.K.
        • Spain
        • Italy
        • France
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Australia
    • Latin America
        • Brazil
        • Mexico
        • Argentina
    • Middle East & Africa
        • Saudi Arabia
        • South Africa

 

Fill the Pre-Order Enquiry Form for the Report @ https://www.grandviewresearch.com/inquiry/6099/ibb

Browse Related Reports:

Tumor Necrosis Factor Inhibitor Drugs MarketSize, Share & Trends Analysis Report By Product (Humira, Enbrel, Remicade, Simponi, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2019 – 2026.

 

Breast Cancer Drugs MarketSize, Share & Trends Analysis Report By Type (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors), By Region, And Segment Forecasts, 2019 – 2025.

 

About Grand View Research

Grand View Research is a U.S. & India-based market research and consultancy firm. It is headquartered in San Francisco. We provide business insights, syndicated research reports, and customized research reports to large as well as small and medium-scale enterprises. Our database features thousands of statistics and in-depth analyses on more than 45 industries. Grand View Research’s extensive database is used by Fortune 500 companies to understand the regional as well as the global business environment.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market

Related Articles